Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

3SBio Inc.

www.3sbio.com

Latest From 3SBio Inc.

Chinese Biosimilar Boom Is Heralded By First Approval

Approval of China's first rituximab biosimilar under new pathway gives developers much-needed boost and an opening to the international market for made-in-China biosimilars helped by favorable regulatory policy changes at home.

China Biosimilars

Biosimilar Boom in China Heralded By First Approval

Approval of China's first rituximab biosimilar under new pathway gives developers much-needed boost and an opening to the international market for made-in-China biosimilars helped by favorable regulatory policy changes at home.

China Biosimilars

Humira Biosimilars Face Complex Asia Outlook As Launches Edge Closer

The Asia Pacific region presents large potential opportunities for the development of biosimilar versions of big-selling original biologics as these come out of protection in the major markets. However the regulatory, reimbursement and commercial situation varies greatly country-by-country, presenting a complex mix of factors affecting the overall market outlook for these up and coming biosimilar products.

Biosimilars Market Access

Humira Biosimilars Face Complex Asia Outlook As Launches Edge Closer

The Asia Pacific region presents large potential opportunities for the development of biosimilar versions of big-selling original biologics as these come out of protection in the major markets. However the regulatory, reimbursement and commercial situation varies greatly country-by-country, presenting a complex mix of factors affecting the overall market outlook for these up and coming biosimilar products.

Asia Pacific Biosimilars
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Generic Drugs
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Inflammation
  • Renal System
  • Alias(es)
  • Shenyang Sunshine Pharmaceutical Co. Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • 3SBio Inc.
  • Senior Management
  • Jing Lou, PhD, Chmn., Pres. & CEO
    Bo Tan, EVP, CFO
    Zhenping Zhu, PhD, Pres., R&D & CSO
  • Contact Info
  • 3SBio Inc.
    Phone: (86) 24 2581 1820
    No. 3 A1, Rd. 10
    Shenyang, 110027
    China
UsernamePublicRestriction

Register